Dilated Cardiomyopathy Market

Dilated Cardiomyopathy Therapeutics Market [Drug Class: Aldosterone Antagonists, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs) and Beta-Blockers] - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

  • Rep Id : TMRGL2293
  • Published On : Mar 2015
  • No. of Pages : 90
  • Category : Pharmaceutical

 
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
     1.3.1 Secondary Research
     1.3.2 Primary Research
1.4 List of Abbreviations
1.5 Assumptions and Stipulations
 
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Dilated Cardiomyopathy Therapeutics Market (2013 & 2020)
2.2 Comparative Analysis: Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Geography, 2013 & 2020 (Value %)
 
Chapter 3 Global Dilated Cardiomyopathy Therapeutics Market Overview
3.1 Market Definition and Overview
     3.1.1 Classification of Cardiomyopathies
     3.1.2 Market Drivers
3.1.2.1 Increasing number of heart failure cases worldwide will lead to rise in demand for effective medications, thereby driving market growth
     3.1.3 Market Restraints
             3.1.3.1 Side effects associated with DCM drugs could restrain market growth
             3.1.3.2 Enhanced relief from use of devices without any side effects will restrain the dilated cardiomyopathy drugs market
     3.1.4 Promising gene and stem cell therapies for DCM treatment may hamper the DCM drugs market growth
     3.1.5 Market Opportunities
     3.1.7 Increasing genericization of DCM drugs
3.2 Market Attractiveness Analysis: Global Dilated Cardiomyopathy Therapeutics Market, by Geography, 2013
3.3 Epidemiology (Prevalence, Cause, Mortality Rate)
3.4 Epidemiology Studies on Dilated Cardiomyopathy
3.5 Causes and Mortality
3.6 Event Impact Analysis
3.7 Competitive Landscape, by Key Players, 2013 (Value %)
     3.7.1 Market share by key players, 2013 (Value %)
 
Chapter 4 Global Dilated Cardiomyopathy Therapeutics Market, by Drug Class
4.1 Introduction
     4.1.1 Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Drug Class 2012 – 2020 (USD Million)
4.2 Aldosterone Antagonists
     4.2.1 Global Aldosterone Antagonists Market Revenue, 2012 - 2020 (USD Million)
4.3 Angiotensin-Converting Enzymes (ACE) Inhibitors
     4.3.1 Global Angiotensin-Converting Enzyme (ACE) Inhibitors Market Revenue, 2012 - 2020 (USD Million)
4.4 Angiotensin II Receptor Blocker (ARBs)
     4.4.1 Global Angiotensin II Receptor Blockers (ARBs) Market Revenue, 2012 - 2020 (USD Million)
4.5 Beta-Blockers
     4.5.1 Global Beta-Blockers Market Revenue, 2012 - 2020 (USD Million)
 
Chapter 5 Pipeline Analysis of Global Dilated Cardiomyopathy Therapeutics Market
5.1 Pipeline Analysis
     5.1.1 Pipeline Analysis : Dilated Cardiomyopathy Therapeutics Market
 
Chapter 6 Global Dilated Cardiomyopathy Therapeutics Market, by Geography
6.1 Introduction
     6.1.1 Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
6.2 North America
     6.2.1 North America Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million)
6.3 Europe
     6.3.1 Europe Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million)
6.4 Asia Pacific
     6.4.1 Asia Pacific Dilated Cardiomyopathy Therapeutics market Revenue, 2012 - 2020 (USD Million)
6.5 Rest of the World (RoW)
     6.5.1 Rest of the World Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million)
 
Chapter 7 Recommendations
7.1 Dilated phase of hypertrophic cardiomyopathy
7.2 Genetic Intervention
 
Chapter 8 Company Profiles
8.1 Array BioPharma, Inc.
     8.1.1 Company Overview
     8.1.2 Financial Overview
     8.1.3 Product Portfolio
     8.1.4 Business Strategies
     8.1.5 Recent Developments
8.2 AstraZeneca plc
     8.2.1 Company Overview
     8.2.2 Financial Overview
     8.2.3 Product Portfolio
     8.2.4 Business Strategies
     8.2.5 Recent Developments
8.3 Celladon Corporation
     8.3.1 Company Overview
     8.3.2 Financial Overview
     8.3.3 Product Portfolio
     8.3.4 Business Strategies
     8.3.5 Recent Developments
8.4 GlaxoSmithKline plc
     8.4.1 Company Overview
     8.4.2 Financial Overview
     8.4.3 Product Portfolio
     8.4.4 Business Strategies
     8.4.5 Recent Developments
8.5 Janssen Pharmaceuticals, Inc.
     8.5.1 Company Overview
     8.5.2 Financial Overview
     8.5.3 Product Portfolio
     8.5.4 Business Strategies
     8.5.5 Recent Developments
8.6 Merck & Co., Inc.
     8.6.1 Company Overview
     8.6.2 Financial Overview
     8.6.3 Product Portfolio
     8.6.4 Business Strategies
     8.6.5 Recent Developments
8.7 Novartis International AG
     8.7.1 Company Overview
     8.7.2 Financial Overview
     8.7.3 Product Portfolio
     8.7.4 Business Strategies
     8.7.5 Recent Developments
8.8 Pfizer, Inc.
     8.8.1 Company Overview
     8.8.2 Financial Overview
     8.8.3 Product Portfolio
     8.8.4 Business Strategies
     8.8.5 Recent Developments
8.9 Sanofi S.A.
     8.9.1 Company Overview
     8.9.2 Financial Overview
     8.9.3 Product Portfolio
     8.9.4 Business Strategies
     8.9.5 Recent Developments
8.10 Teva Pharmaceutical Industries Ltd.
     8.10.1 Company Overview
     8.10.2 Financial Overview
     8.10.3 Product Portfolio
     8.10.4 Business Strategies
     8.10.5 Recent Developments
8.11 Vericel Corporation
     8.11.1 Company Overview
     8.11.2 Financial Overview
     8.11.3 Product Portfolio
     8.11.4 Business Strategies
     8.11.5 Recent Developments

List of Tables
 
TABLE 1 Market Snapshot: Global Dilated Cardiomyopathy Therapeutics Market (2013 & 2020)
TABLE 2 Classification of Cardiomyopathies
TABLE 3 Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Drug Class, 2012 - 2020 (USD Million)
TABLE 4 Pipeline Analysis : Dilated Cardiomyopathy Therapeutics Market
TABLE 5 Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)

 List of Figures
 
FIG. 1 Dilated Cardiomyopathy Therapeutics Market: Market Segmentation
FIG. 2 Global Dilated Cardiomyopathy Therapeutics Market, by Drug Class, 2013 (USD Million)
FIG. 3 Comparative Analysis: Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Geography, 2013 & 2020 (Value %)
FIG. 4 Market Attractiveness Analysis: Global Dilated Cardiomyopathy Therapeutics Market, by Geography, 2013
FIG. 5 Market Share Analysis: Global Dilated Cardiomyopathy Therapeutics Market, by Key Players, 2013 (Value %)
FIG. 6 Global Aldosterone Antagonists Market Revenue, 2012 - 2020 (USD Million)
FIG. 7 Global Angiotensin-Converting Enzyme (ACE) Inhibitors Market Revenue, 2012 - 2020 (USD Million)
FIG. 8 Global Angiotensin II Receptor Blockers (ARBs) Market Revenue, 2012 - 2020 (USD Million)
FIG. 9 Global Beta-Blockers Market Revenue, 2012 - 2020 (USD Million)
FIG. 10 North America Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 11 Europe Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 12 Asia Pacific Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 13 Rest of the World Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 14 Array BioPharma, Inc.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 15 AstraZeneca plc: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 16 GlaxoSmithKline plc: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 17 Johnson & Johnson (Pharmaceutical Division): Annual Revenue 2011 – 2013 (USD Million)
FIG. 18 Merck & Co., Inc.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 19 Novartis International AG: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 20 Pfizer, Inc.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 21 Sanofi S.A.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 22 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 23 Vericel Corporation: Annual Revenue, 2011 – 2013 (USD Million)

.